MRVI: Maravai LifeSciences Holdings, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 700.00
Enterprise Value ($M) 911.55
Book Value ($M) 776.41
Book Value / Share 5.47
Price / Book 0.90
NCAV ($M) 14.01
NCAV / Share 0.10
Price / NCAV 49.96

Profitability (mra)
Return on Invested Capital (ROIC) -0.16
Return on Assets (ROA) -0.15
Return on Equity (ROE) -0.25

Liquidity (mrq)
Quick Ratio 9.94
Current Ratio 10.74

Balance Sheet (mrq) ($M)
Current Assets 679.10
Assets 1,278.21
Liabilities 665.09
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-14 13G/A Point72 Asset Management, L.P. 2.60 -44.53
11-13 13G/A 12 West Capital Management LP 9.90 20.75
11-13 13G/A Maravai Life Sciences Holdings 2, Llc 51.81 -7.06
11-08 13G BlackRock, Inc. 7.40 0.00
10-29 13G/A Millennium Management Llc 3.10 -39.31
02-13 13G/A Vanguard Group Inc 7.57 -3.72

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-05-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-01-14 613,938 1,979,761 31.01
2025-01-13 965,679 2,509,293 38.48
2025-01-10 1,753,930 6,178,092 28.39

(click for more detail)

Similar Companies
MNMD – Mind Medicine (MindMed) Inc. MRNA – Moderna, Inc.
MRSN – Mersana Therapeutics, Inc. MYGN – Myriad Genetics, Inc.
NBIX – Neurocrine Biosciences, Inc.


Financial data and stock pages provided by
Fintel.io